Adoptive cell transfer of T-cell receptor-engineered lymphocytes: Lessons from recent modeling

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1671-1673

  Ribas, Antoni ^a,b   Koya, Richard C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; imaging; immunotherapy; T cell receptor

Indexed keywords

T LYMPHOCYTE RECEPTOR;

BIOLUMINESCENCE; CELL THERAPY; CELL TRANSFER; IMMUNE SYSTEM; IMMUNOTHERAPY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADOPTIVE TRANSFER; ANIMALS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MODELS, ANIMAL; MOLECULAR IMAGING; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 78650196293     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.137     Document Type: Review

References (19)

1. Roszkowski JJ, Yu DC, Rubinstein MP, Mckee MD, Cole DJ, Nishimura MI: CD8-independent tumor cell recognition is a property of the T-cell receptor and not the T-cell. J. Immunol. 170(5), 2582-2589 (2003).
2. Morgan RA, Dudley ME, Yu YY et al.: High effciency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171(6), 3287-3295 (2003).
3. Thomas S, Xue SA, Cesco-Gaspere M et al.: Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modifed human T cells. J. Immunol. 179(9), 5803-5810 (2007).
4. Johnson LA, Morgan RA, Dudley ME et al.: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535-546 (2009).
5. Bobisse S, Rondina M, Merlo A et al.: Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 69(24), 9385-9394 (2009).
6. Johnson LA, Heemskerk B, Powell DJ Jr et al.: Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infltrating lymphocytes. J. Immunol. 177(9), 6548-6559 (2006).
7. Labrecque N, Whitfeld LS, Obst R, Waltzinger C, Benoist C, Mathis D: How much TCR does a T-cell need? Immunity 15(1), 71-82 (2001).
8. Szymczak AL, Workman CJ, Wang Y et al.: Correction of multi-gene defciency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 22(5), 589-594 (2004).
9. Scholten KB, Kramer D, Kueter EW et al.: Codon modifcation of T-cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119(2), 135-145 (2006).
10. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA: Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66(17), 8878-8886 (2006).
11. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfde bond. Cancer Res. 67(8), 3898-3903 (2007).
12. Heemskerk MH, Hagedoorn RS, Van Der Hoorn MA et al.: Effciency of T-cell receptor expression in dual-specifc T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109(1), 235-243 (2007).
13. Koya RC, Mok S, Comin-Anduix B et al.: Kinetic phases of distribution and tumor targeting by T-cell receptor engineered lymphocytes inducing robust antitumor responses. Proc. Natl Acad. Sci. USA 107(32), 14286-14291 (2010).
14. Weinhold M, Sommermeyer D, Uckert W, Blankenstein T: Dual T-cell receptor expressing CD8+ T cells with tumor- and self-specifcity can inhibit tumor growth without causing severe autoimmunity. J. Immunol. 179(8), 5534-5542 (2007).
15. Hagani AB, Riviere I, Tan C, Krause A, Sadelain M: Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection. J. Gene Med. 1(5), 341-351 (1999).
16. Engels B, Cam H, Schuler T et al.: Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14(12), 1155-1168 (2003).
17. Surh CD, Sprent J: Homeostatic T-cell proliferation: how far can T cells be activated to self-ligands? J. Exp. Med. 192(4), F9-F14 (2000).
18. Yaghoubi SS, Jensen MC, Satyamurthy N et al.: Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract. Oncol. 6(1), 53-58 (2009).
19. Dobrenkov K, Olszewska M, Likar Y et al.: Monitoring the effcacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J. Nucl. Med. 49(7), 1162-1170 (2008).